Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand the study and are willing to sign a consent form
• People who are 18 years of age or older
• People who have been diagnosed (either through clinical assessment or tissue testing) with liver cancer (hepatocellular carcinoma) that can be removed by surgery but is beyond a certain size or spread threshold known as the Milan criteria (confirm with trial site)
• People who have not received any previous treatment for their liver cancer
• People whose liver is functioning at a good level, as measured by a scoring system called Child-Pugh class A (confirm with trial site)
• People whose general physical health and ability to carry out daily activities is rated at 0 or 1 on a standard medical scale (meaning fully active or restricted in strenuous activity only)
• People whose doctors expect them to live for more than 6 months
• People whose organs and bone marrow are working well enough to participate in the study (confirm with trial site for specific lab values)

Who may not be able to join:

• People whose liver cancer is a specific type other than standard hepatocellular carcinoma, such as bile duct cancer, mixed liver cancer, sarcomatoid liver cancer, or fibrolamellar liver cancer
• People who have had an organ transplant or have a history of a condition where the liver fails to remove toxins from the blood (hepatic encephalopathy)
• People who have a build-up of fluid in the chest, abdomen, or around the heart that is causing symptoms and needs to be drained
• People who have had bleeding from enlarged veins in the food pipe or stomach (caused by high blood pressure in the liver's blood supply) in the past 6 months, or who have been found to have severely enlarged veins on a camera examination in the past 3 months, or who are considered at high risk of such bleeding
• People who have experienced a serious blood clot or blockage in a blood vessel in the past 6 months, including heart attack, unstable chest pain, stroke, mini-stroke, blood clot in the lungs, or deep vein clot
• People who have had a life-threatening bleeding episode in the past 3 months
• People with a serious tendency to bleed, a blood clotting disorder, or who are currently receiving treatment to dissolve blood clots
• People who regularly need to take blood-thinning or antiplatelet medications such as high-dose aspirin (more than 325 mg per day), dipyridamole, or clopidogrel
• People with blood pressure that cannot be controlled with medication (above 140/90 mmHg), or who have had a history of a severe high blood pressure crisis or high blood pressure affecting the brain
• People with significant heart failure causing symptoms, poorly controlled irregular heartbeat, a condition called long QT syndrome, or an abnormal heart electrical reading above a certain level on testing
• People who have had, in the past 6 months, a hole or abnormal opening in the gut, a bowel blockage requiring special feeding through a drip, large bowel surgery with ongoing complications, Crohn's disease, ulcerative colitis, or long-term persistent diarrhoea
• People who have had major surgery (such as brain, chest, or abdominal surgery) within 4 weeks before joining, or who have wounds, ulcers, or fractures that have not healed, or who have had a minor surgical procedure (other than placing an IV line) within 7 days before joining
• People with a history of serious lung diseases such as pulmonary fibrosis, interstitial lung disease, dust-related lung disease, drug-induced lung disease, or severely reduced lung function
• People with active hepatitis B or C infection at levels above certain thresholds, or with certain combinations of hepatitis markers (confirm with trial site for specific values)
• People who currently have active tuberculosis (TB), are currently being treated for TB, or completed TB treatment within the past year
• People who have HIV infection or a known syphilis infection
• People with a severe active infection that is not well controlled
• People who have an active autoimmune disease (where the immune system attacks the body) that required systemic medical treatment within the past 2 years — though some hormone replacement therapies at normal doses are permitted (confirm with trial site)
• People who have taken immune-suppressing medications within the past 4 weeks, with some exceptions for low-dose or inhaled/topical steroids (confirm with trial site)
• People who have received a live vaccine within the past 4 weeks, or who plan to receive one during the study
• People who have used immune-boosting agents such as thymosin, interferons, or interleukins within the past 2 weeks (with some exceptions for local use)
• People with uncontrolled metabolic conditions, serious non-cancer organ disease, or other conditions that the medical team considers too risky for study participation
• People who have been diagnosed with another cancer within the past 5 years, with some exceptions for certain skin cancers or cancers that were completely cured (confirm with trial site)
• People who have previously received treatments targeting blood vessel growth (anti-angiogenic agents) or certain immunotherapy treatments including anti-PD-1, anti-PD-L1/L2, or anti-CTLA-4 antibodies
• People who are known to have had a serious allergic reaction to sintilimab, bevacizumab, or similar antibody-based medicines
• People who have taken part in another clinical trial within the past 4 weeks
• People who are pregnant or breastfeeding
• People who have other health conditions, mental health conditions, or abnormal test results that the trial doctors believe would make participation unsafe or affect the study results

Important: Always verify eligibility with the trial site directly before applying.